Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Recruiting · NCT07088211 · Registry updated 2026-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-06-18 | NCT07088211 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 77 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai | China | 9 |